Moderna and Merck report phase 3 melanoma vaccine benefit after data leak jolts investors

YOUR DAILY READING

Daily Briefing

Search briefing Original language

THE WORLD YOU TRACK

Following

Material changes to events and evidence-backed topics you chose to follow. Repeated coverage without a new fact stays quiet.

EDITOR-CONFIRMED STORYLINES

Topics

Evidence-backed developments connected across several events, dates and independent sources.

CITY GUIDE

Local Life

Plan local events in a calendar or browse them as cards, city by city.

PAID FEATURE

PRIVATE BY DEFAULT

My Subscriptions

This area contains only RSS or Atom sources you add yourself. Editorial feeds stay in Daily Briefing and never appear here.

READ LATER

Read Later

YOUR STUDY SHELF

Learning Library

Every learning edition you request stays here, including materials still being prepared.

LANGUAGE ENTITLEMENTS

Learning Languages

English is included for every account. Language slots and monthly AI generation allowances are separate.

ACCOUNT & PRIVACY

Account Settings

HUMAN REVIEW REQUIRED

Editorial Review

Audience size never promotes a source automatically. Rights decisions and new-city requests require a recorded human review.

Storyline evidence desk

A topic stays internal until it has at least three connected events across multiple dates and sources. Eligible candidates still require a human to choose a specific public name.

Event desk controls

Manual merges are archived reversibly, splits retain the original membership as inactive, and isolated events are excluded from automatic matching.

Moderna and Merck report phase 3 melanoma vaccine benefit after data leak jolts investors